SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as the community debates the geopolitical and economic ramifications of a new memorandum of understanding between the U.S. and Iran. Discussions are heavily focused on the terms of the deal, the potential for market manipulation via official social media channels, and the broader concerns regarding current economic stability.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending following the announcement of a joint research agreement with Honda to develop solid-state battery technology and manufacturing processes. Community sentiment is mixed as investors weigh the significance of a major OEM validation against the reality that the partnership focuses on research rather than immediate mass production.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

The iShares 20+ Year Treasury Bond ETF (TLT) remains a focal point as traders react to persistent inflation concerns, the ongoing Iran-U.S. peace negotiations, and expectations surrounding the new Federal Reserve chair's potential policy direction. Community discourse is currently split between those anticipating a major bond market rally fueled by a potential end to geopolitical instability and others bracing for continued volatility as they monitor labor data and interest rate signals.

KLA Corp. engages in the supply of process control and yield management solutions for the semiconductor and related nano-electronics industries. The company operates through the following segments: Semiconductor Process Control, Specialty Semiconductor Process, and PCB, Display and Component Inspection. The Semiconductor Process Control segment provides a comprehensive portfolio of inspection, metrology and data analytics products and related services. The Specialty Semiconductor Process segment develops and sells advanced vacuum deposition and etching process tools. The PCB, Display and Component Inspection segment enables electronic device manufacturers to inspect, test and measure PCBs, flat panel displays and ICs to verify their quality. Its products include manufactured chips, reticle, packaging, surface profilers, nanochemical testers, KT pro equipment, and compound semiconductors. The company was founded on July 9, 1975 and is headquartered in Milpitas, CA.

KLA Corp.

KLA Corp is trending as investors weigh strong AI-driven infrastructure demand against sector-wide volatility triggered by semiconductor equipment peers. The community is actively discussing the company's role as an essential 'toll collector' in the chip manufacturing process while monitoring analyst price target adjustments and broader capital equipment cycles.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors react to strong quarterly growth and ongoing speculation regarding potential strategic interest or merger activity. The community is actively debating the company's valuation relative to its revenue expansion, the impact of pending litigation, and the significant institutional accumulation seen in recent filings.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors rotate into its QNX division, which is increasingly positioned as the critical safety-certified operating system for the emerging Physical AI and robotics sectors. The community is actively discussing recent analyst price target upgrades, positive institutional momentum, and the high-growth potential of the Alloy Kore platform ahead of upcoming earnings.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is seeing heightened investor attention following a combination of positive clinical data for its oncology portfolio and ongoing M&A speculation, including potential interest in selling its orthopedics unit to focus on high-growth assets. While the stock has attracted defensive capital, community sentiment remains split between excitement over the company's aggressive drug pipeline expansion and concerns regarding persistent talc-related litigation.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently facing intense bearish sentiment and significant volatility, with the community actively debating whether the token is at a generational bottom or suffering from terminal structural decay. Investors are focused on deep price corrections and the impact of broader market macro-trends, while some remain hopeful that the project's enterprise-grade technology and tokenization initiatives will lead to a long-term cyclical recovery.

Permian Resources Corp. is an oil and natural gas company, which focuses on returns to stakeholders through the responsible acquisition, optimization and development of crude oil and associated liquids-rich natural gas reserves. The company was founded on December 18, 2025 and is headquartered in Midland, TX.

Permian Resources Holdings Inc. - Ordinary Shares - Class A

Permian Resources Corp - Ordinary Shares - Class A

Permian Resources is currently a major focus for investors as the escalating conflict in the Middle East and the closure of the Strait of Hormuz drive significant upside for domestic oil producers. Community sentiment remains highly bullish, with many traders emphasizing the stock's strong fundamentals and high free cash flow as key pillars to withstand the market volatility surrounding potential energy supply shocks.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased community interest driven by recent mentions in a Google research paper regarding quantum-resistant security and the network's post-quantum cryptography capabilities. While bulls are focused on accumulation and potential institutional adoption, others remain skeptical, engaging in ongoing debates about historical performance and price volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)

Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilurgisertib, an investigational oral activin receptor-like kinase 2 (ALK2) inhibitor, in adolescents and adults (12 years of age) with...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on June 10, 2026, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 10,100 shares of common stock and 13,350...

Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report?

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva (FOP) will be presented at ENDO 2026, the...

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced new data from its rare liver disease programs. Late-breaking results from the Phase 2b VISTAS study of volixibat in PSC and Phase 2b AZURE-1 study of brelovitug in HDV, alongside data featuring its...

Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will present new data at the European Association for the Study of the Liver (EASL) International Liver Congress 2026, taking place May 27-30, 2026, in Barcelona, Spain. Presentations span Mirums...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on May 11, 2026, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 22,950 shares of common stock and 31,300...

Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes

Mirum Pharmaceuticals, Inc. (Mirum) (Nasdaq: MIRM), a leading rare disease company, today announced the pricing of its offering of $600.0 million aggregate principal amount of 0.00% convertible...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Mirum Pharmaceuticals Inc

MIRM Stock Clocks Best Day In 4.5 Months On Liver Disease Trial Data: Retail Eyes Buyout At A Premium

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$107.13
Prev Close	$102.04
Open	$104.48
Dividend Yield	0.00%
50-Day Moving Average	$98.63
Beta	0.85
Avg. Volume	1.32M
PE Ratio	-7.87

52-Week High	$114.99
52-Week Low	$47.89
Market Capitalization	$6.22B
EPS (Annual)	-$0.4654
Price to Book	26.92
Revenue Per Employee	$1.4M

MIRMMirum Pharmaceuticals Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MIRM News